126 related articles for article (PubMed ID: 11728242)
1. Drug treatment of peripheral vascular disease.
Eberhardt RT; Coffman JD
Heart Dis; 2000; 2(1):62-74. PubMed ID: 11728242
[TBL] [Abstract][Full Text] [Related]
2. Medical treatment of peripheral vascular disease: are there new perspectives?
Smit AJ
Vasa Suppl; 1992; 34():20-4. PubMed ID: 1529413
[TBL] [Abstract][Full Text] [Related]
3. DVT and pulmonary embolism: Part II. Treatment and prevention.
Ramzi DW; Leeper KV
Am Fam Physician; 2004 Jun; 69(12):2841-8. PubMed ID: 15222649
[TBL] [Abstract][Full Text] [Related]
4. The use of antithrombotic drugs in older people.
Tufano A; Cerbone AM; Di Minno G
Minerva Med; 2002 Feb; 93(1):13-26. PubMed ID: 11850611
[TBL] [Abstract][Full Text] [Related]
5. [The therapy of Raynaud's phenomenon].
Di Giacinto G
Clin Ter; 1993 Feb; 142(2):161-74. PubMed ID: 8472530
[TBL] [Abstract][Full Text] [Related]
6. Warfarin-associated multiple digital necrosis complicating heparin-induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis.
Warkentin TE; Whitlock RP; Teoh KH
Am J Hematol; 2004 Jan; 75(1):56-62. PubMed ID: 14695634
[TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin system mediators and Raynaud's phenomenon.
Wood HM; Ernst ME
Ann Pharmacother; 2006 Nov; 40(11):1998-2002. PubMed ID: 17003081
[TBL] [Abstract][Full Text] [Related]
8. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
Hull RD; Pineo GF
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Raynaud's phenomenon.
García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Pardo-Santos R; Levy R; Maldonado CG; Chávez GP; Cervera R
Autoimmun Rev; 2008 Oct; 8(1):62-8. PubMed ID: 18692160
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and management of scleroderma peripheral vascular disease.
Herrick A
Rheum Dis Clin North Am; 2008 Feb; 34(1):89-114; vii. PubMed ID: 18329535
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight heparins: the optimal treatment for venous thromboembolism.
Daskalopoulos ME; Daskalopoulou SS; Liapis CD
Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulants in the treatment of deep vein thrombosis.
Merli G
Am J Med; 2005 Aug; 118 Suppl 8A():13S-20S. PubMed ID: 16125510
[TBL] [Abstract][Full Text] [Related]
13. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
14. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
15. Comparison of unfractionated heparin vs low molecular weight heparin in the treatment of acute deep vein thrombosis.
Naz R; Naz S; Mehboob M; Khalid GH
J Coll Physicians Surg Pak; 2005 Oct; 15(10):601-4. PubMed ID: 19810295
[TBL] [Abstract][Full Text] [Related]
16. New drug therapy in peripheral vascular disease.
Coffman JD
Med Clin North Am; 1988 Jan; 72(1):259-65. PubMed ID: 3276987
[TBL] [Abstract][Full Text] [Related]
17. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Fries R; Shariat K; von Wilmowsky H; Böhm M
Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
[TBL] [Abstract][Full Text] [Related]
18. Anorexia nervosa and Raynaud's phenomenon: a case report.
Yucel B; Uzum AK; Ozbey N; Kamali S; Yager J
Int J Eat Disord; 2007 Dec; 40(8):762-5. PubMed ID: 17607716
[TBL] [Abstract][Full Text] [Related]
19. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
20. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
